$ISRG (Intuitive Surgical, Inc.)

$ISRG {{ '2016-10-18T20:53:02+0000' | timeago}} • Webcast

$ISRG posted a solid performance in 3Q16 with increasing customer adoption of procedures and growth in system placements. Global procedure growth was over 14% YoverY driven mainly by growth in US general surgery and growth in the use of da Vinci surgical systems outside the US.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$ISRG {{ '2017-10-19T20:24:48+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical Earnings AlphaGraphic: Q3 2017 Highlights

$ISRG {{ '2017-07-21T12:26:16+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ISRG {{ '2017-07-20T20:21:13+0000' | timeago}} • Announcement

In 2Q17, $ISRG's service revenue rose 11% to $142MM while instrument and accessory revenue jumped 17% to $398MM. Intuitive Surgical ended the second quarter with $3.4Bil in cash, cash equivalents, and investments.

$ISRG {{ '2017-07-20T20:16:13+0000' | timeago}} • Announcement

In 2Q17, revenue for $ISRG jumped 13% to $756MM while net income soared 20% to $222MM or $5.77 per diluted share. Non-GAAP net income was $228MM or $5.95 per diluted share, with systems revenue increased by approximately 7% to $216MM.

$ISRG {{ '2017-05-30T20:51:18+0000' | timeago}} • Announcement

$ISRG's new da Vinci X Surgical System received FDA clearance in the US. The da Vinci X System will provide surgeons and hospitals with access to some of the most advanced robotic-assisted surgery technology at a lower cost.

$ISRG {{ '2017-04-18T22:04:46+0000' | timeago}} • Webcast

$ISRG stated that on the da Vinci X, the instruments are going to be similar to the Xi. Additionally, instruments on X are the same family as the Xi. On additional instruments, the company has a portfolio of instruments it's working on and $ISRG is expanding its stapler line, to be a full line sapling system.

$ISRG {{ '2017-04-18T21:34:45+0000' | timeago}} • Webcast

$ISRG said that on the procedure guidance, the company expects 2017 procedure growth to be driven by US general surgery and international procedure. On the Australia work, which was on the flexible robotics platform, they are in patient follow up now. The company expects them to be presenting publicly in the fall.

$ISRG {{ '2017-04-18T21:00:54+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q1 2017 highlights

$ISRG {{ '2017-04-18T20:26:37+0000' | timeago}} • Announcement

For 1Q17, $ISRG's Instruments and Accessories revenue grew 18.22% YoY to $380.8MM, helped by nearly 18% growth in da Vinci procedure volume. Service revenue grew by 12.61% to $140.2MM, while Systems revenue for the quarter rose by 3.58% to $153.2MM from a year ago.

$ISRG {{ '2017-04-18T20:22:23+0000' | timeago}} • Announcement

Medical devices company $ISRG reported higher 1Q17 earnings, helped by higher revenue. Net income for the quarter rose 31.81% to $179.8MM or $4.67 per share from $136.4MM or $3.54 per share a year ago. Revenue grew 13.4% YoY to $674.2MM. Excluding items, $ISRG earned $5.09 per share.

$ISRG {{ '2017-04-18T12:04:26+0000' | timeago}} • Announcement

$ISRG said that equity awards, approved by the Compensation Committee of the BoD, which consists entirely of Independent Directors, were made to 57 new employees. The equity awards were granted under $ISRG 2009 Commencement Incentive Plan, which the board adopted for the granting of equity awards to new employees.

$ISRG {{ '2017-02-14T12:30:20+0000' | timeago}} • Announcement

$ISRG said that equity awards, approved by the Compensation Committee of the BoD, which consists entirely of Independent Directors, were made to 92 new employees. The equity awards were granted under the 2009 Commencement Incentive Plan, which the Board adopted for the granting of equity awards to new employees.

$ISRG {{ '2017-01-24T22:18:13+0000' | timeago}} • Webcast

$ISRG said that in 2017, the company expects its pro forma gross profit margin to be in the range of 69-71% of net revenue. The company also expects to grow pro forma 2017 operating expenses between 15-18% above 2016 levels.

$ISRG {{ '2017-01-24T22:10:09+0000' | timeago}} • Webcast

$ISRG ended 4Q16 with cash and investments of $4.8Bil, up from $4.6Bil as of Sept. 30, 2016. This increase was mainly driven by cash generated from operations and proceeds from stock option exercises. During 4Q16, the company repurchased 55,000 shares for $34MM.

$ISRG {{ '2017-01-24T21:48:52+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical Earnings AlphaGraphics: Q4 and FY16 Highlights

$ISRG {{ '2017-01-24T21:28:33+0000' | timeago}} • Announcement

For 3Q16, $ISRG's Instruments and Accessories revenue rose 18.64% YoverY to $386.3MM, helped by growth in U.S. general surgery procedures and worldwide urologic procedures. Service revenue grew by 12.06% to $134.7MM, while Systems revenue for the quarter rose by 2.25% to $235.9MM from a year ago.

$ISRG {{ '2017-01-24T21:23:55+0000' | timeago}} • Announcement

Medical devices company $ISRG posted higher 4Q16 earnings, helped by higher revenue. Net income for the quarter rose 7.36% to $204MM or $5.13 per share from $190MM or $4.99 per share a year ago. Revenue grew 11.88% YoverY to $756.9MM. Excluding items, $ISRG earned $6.09 per share.

$ISRG {{ '2016-10-18T22:04:52+0000' | timeago}} • Webcast

$ISRG is seeing encouraging trends in hernia in terms of rates of procedure adoption and surgeon retention. The utilization within the existing surgeon population as they continue to do more procedures has been a strong point in the way the technology has been adopted.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
AIT (Applied Industrial Technologies, Inc.)
Friday, August 11 2017 - 2:00pm
XRAY (DENTSPLY International Inc.)
Wednesday, August 9 2017 - 12:30pm
OPK (Opko Health, Inc.)
Tuesday, August 8 2017 - 8:30pm
STE (Steris Plc)
Tuesday, August 8 2017 - 2:00pm
IVC (Invacare Corporation)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
MSA (MSA Safety Incorporated)
Friday, August 4 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
MASI (Masimo Corporation)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
KAMN (Kaman Corporation)
Tuesday, August 1 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm
MTD (Mettler-Toledo International Inc.)
Thursday, July 27 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, July 27 2017 - 8:30pm
JCI (Johnson Controls Inc.)
Thursday, July 27 2017 - 3:00pm

AlphaGraphics you may like